New US approval for BeiGene’s Tevimbra

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).

Tevimbra, which generated $621 million sales in 2024, is marketed by Sino-America biotech BeiGene (HKEX: 06160), whose shares were up 3.6% at 234.46 renminbi today.

“The approval of Tevimbra in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease,” said Dr Nataliya Uboha, associate professor, University of Wisconsin, Carbone Cancer Center, adding; “There is a critical need for effective treatments of ESCC, and TEVIMBRA has been shown to improve outcomes in this patient population.”